VVCRD Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$5,000	1
2023	Research	$29,200	6
2021	Research	$42,586	10
2020	Research	$5,000	1
2019	Research	$20,000	3

Breakdown

Who paid Research payments · program years 2019–2024

Gilead Sciences, Inc. $29,086 7 payments
Allergan Inc. $25,000 4 payments
Bausch Health US, LLC $18,500 3 payments
Pfizer Inc. $16,700 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $8,500 2 payments
Celgene Corporation $4,000 1 payment

Studies the money was for Research payments · program years 2019–2024

An Openlabel Singlearm Study to Evaluate the Efficacy Pharmacokinetics and Safety of Etrasimod in Adolescent Subjects With Moderately to Severely Active Ulcerative Colitis $15,700 3 payments
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $15,000 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-Release Tablets Administered Once Daily in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis $13,500 2 payments
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease $9,440 1 payment
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease $9,440 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of Tak-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on A Gluten-Free Diet $8,500 2 payments
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease $5,000 1 payment
A 52-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active- Controlled, Operationally Seamless Phase 2B3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohns Disease $5,000 1 payment
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) $5,000 1 payment
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh $5,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.